Posted: January 19, 2013 - 12:01 am ET
Ongoing shortages of sterile injectable drugs have triggered a wave of investment in new and existing compounding pharmacies, which so far, at least, hasn't alleviated the shortages.
A combination of high margins, persistent drug shortages and cash-strapped hospitals unwilling to invest in their own sterile pharmacy facilities has ignited interest from a number of investors. They include private equity firms, drug and device manufacturers and healthcare management firms.
“This whole industry popped up,” said Lou Diorio, a principal with LDT Health Solutions, a pharmacy consulting firm. “It's gained such momentum over the last three or four years.”
A combination of high margins, persistent drug shortages and cash-strapped hospitals unwilling to invest in their own sterile pharmacy facilities has ignited interest from a number of investors. They include private equity firms, drug and device manufacturers and healthcare management firms.
“This whole industry popped up,” said Lou Diorio, a principal with LDT Health Solutions, a pharmacy consulting firm. “It's gained such momentum over the last three or four years.”
Read more: Drug shortages lead to investors buying up compounders | Modern Healthcare http://www.modernhealthcare.com/article/20130119/MAGAZINE/301199973#ixzz2IU9GV6UW
?trk=tynt